ライフサイエンスコーパス: femoral vein

1 was randomized (136 subclavian vein and 134 femoral vein).

2 tinuous exposure to flowing blood within rat femoral vein.

3 oxide in a manner similar to that of porcine femoral vein.

4 denosine 140 mcg/kg per minute via a central femoral vein.

5 ges acquired within the pump circuit and the femoral vein.

6 ioMEMS) is approved for implantation via the femoral vein.

7 of the right superficial femoral artery and femoral vein.

8 ) in PBS or a PBS-alone injection into right femoral vein.

9 We infused hyperosmolar sucrose via the femoral vein.

10 ization of the right femoral artery and left femoral vein.

11 heter with a snare introduced via the common femoral vein.

12 atic or asymptomatic DVT in the popliteal or femoral veins.

13 elial cells or endothelial cells of isolated femoral veins.

14 Two 8-Fr catheters were placed into the femoral veins.

15 ers inserted in the brachial artery and both femoral veins.

16 vigation-guided mapping/ablation with normal femoral vein access (49); and Group C, remote magnetic n

17 Using femoral vein access, a steerable guide catheter was plac

18 eight healthy volunteers once with bilateral femoral vein and artery catheters during a 3-h basal per

19 Catheters were placed in the femoral vein and artery, and in the pulmonary artery.

20 e then tracheostomized and cannulated in one femoral vein and artery.

21 Bolus (0.3 mL) was injected into the femoral vein and hemodynamics monitored.

22 uptake and definitive in vivo images of both femoral vein and pulmonary thrombi show that 99mTc-P748

23 catheters were surgically implanted into the femoral vein and sepsis was induced by cecal ligation an

24 catheters were inserted into the jugular and femoral veins and femoral artery.

25 Patients with postthrombotic femoral veins and those who received multiple stents wer

26 operator characteristics analyses were 0.76 (femoral vein) and 0.77 (popliteal vein) based on inciden

27 e, sampling (artery and portal, hepatic, and femoral veins) and infusion (vena cava, duodenum) cathet

28 rosal sinus, and the internal jugular vein), femoral vein, and radial artery of patients undergoing i

29 d, and cannulated in one femoral artery, one femoral vein, and the right jugular vein.

30 Saline injection via the right femoral vein appears to have a higher diagnostic yield f

31 othelial cells and when placed into isolated femoral vein as well as increased endothelial cell monol

32 embolic stroke and received treatment via a femoral vein at 4 h post-stroke.

33 es were taken from the LA, right atrium, and femoral vein at baseline and at 15 min in all 3 groups.

34 ariable Cox regression model, postthrombotic femoral veins at baseline (hazard ratio, 2.64 [95% CI, 1

35 In contrast,femoral vein ATP infusion did not alter LBF, (.)Q or MAP

36 re obtained from one femoral artery and both femoral veins before and during the clamp.

37 Systemic (femoral vein) but not coronary sinus tumor necrosis fact

38 They underwent tracheostomy, jugular and femoral vein cannulation, femoral artery cannulation, ca

39 ture suggest that thrombosis associated with femoral vein catheterization should be considered when c

40 of a heretofore undescribed complication of femoral vein catheterization, phlegmasia cerulea dolens

41 er risk of pneumothorax than jugular-vein or femoral-vein catheterization.

42 mon femoral vein (CFV), proximal superficial femoral vein (CFV), mid-SFV, distal SFV, and popliteal v

43 s were categorized at five locations: common femoral vein (CFV), proximal superficial femoral vein (C

44 n alone as a placebo by injection into right femoral vein, directly into the left ventricular (LV) ca

45 Glutathione also elevated cGMP levels in the femoral vein during ACH infusion from 17.6 +/- 3 to 23.3

46 ) was infused over the next 3 min of CPR via femoral vein followed by up to three defibrillation atte

47 958 in the internal jugular and 3,188 in the femoral vein for a total of 113,652 catheter days.

48 The animals had a catheter inserted into the femoral vein for administration of 5-HT (0.00375 mg) and

49 proach (femoral artery diagnostic access and femoral vein for temporary pacing lead placement) for se

50 serted either in the internal jugular or the femoral vein had greater risk to be colonized than cathe

51 dvance the delivery sheath beyond the common femoral vein in 1).

52 cs on blood from artery, coronary sinus, and femoral vein in 110 patients with or without heart failu

53 TPV implant was via the femoral vein in 17 patients, the right internal jugular

54 ed into the subclavian, internal jugular, or femoral vein in two randomized trials during 1998-2000 w

55 re unit (ICU) to the subclavian, jugular, or femoral vein (in a 1:1:1 ratio if all three insertion si

56 1 and femoral artery in 20) and anterograde (femoral vein) in 2.

57 erval [0.30-0.70], I=0%; subclavian vein vs. femoral vein, incidence density ratio 0.27; 95% confiden

58 type second harmonic ultrasound system after femoral vein injection of AF0145 (10 to 40 mg) in 13 clo

59 Additionally, following femoral vein injury, Tfpi(+/-);F8(-/-) mice with Tfpi(-/

60 t puncture set was introduced from the right femoral vein into the left renal vein.

61 Animals are first anesthetized, then one femoral vein is exposed and subjected to a standardized,

62 The femoral vein is widely accepted as an insertion site wit

63 ypass-related complications (cerebral edema, femoral vein laceration).

64 After thrombolysis, 99 iliac and five femoral vein lesions were treated with stents.

65 subclavian, 3053 internal jugular, and 1554 femoral vein) met the inclusion criteria, one of which w

66 ale Swiss mice after femoral artery (n = 7), femoral vein (n = 6) or intraperitoneal (n = 6) injectio

67 6), common femoral (n = 27), and superficial femoral veins (n = 4).

68 , n=37; and Group 3, cadaveric cryopreserved femoral vein, n=11.

69 red, and changes in leg blood flow (LBF) and femoral vein nitric oxide nitrite plus nitrate (NOx) flu

70 genic injury was subsequently induced in the femoral vein of each mouse and the area (size) of thromb

71 of the kinetics of a thrombus induced in the femoral vein of the animal.

72 inserted into both femoral arteries and one femoral vein of the support rat.

73 inetics of thrombus formation induced in the femoral veins of the experimental mice were compared.

74 ion at rest, (3) passive exercise (n=10), (4)femoral vein or artery ATP infusion (n=6), and (5) cycli

75 ide) was administered into the right atrium, femoral vein, or endotracheal tube.

76 In 10 patients, femoral vein plasma cyclic guanylate monophosphate (cGMP

77 empted tricuspid valve repair procedure upon femoral vein puncture.

78 Placebo administered into the femoral vein resulted in a significant increase in perce

79 rine administration via the right atrium and femoral vein resulted in significant increases in plasma

80 ery, vena cava, portal vein, femoral artery, femoral vein, saphenous vein, pulmonary vein, and pulmon

81 ous conduits must be utilized, cryopreserved femoral veins seem to provide superior patency rates.

82 The needle was introduced via a 12-F femoral vein sheath and advanced into the IVC by using a

83 l, vaginal mucosa, and clitoris assessments; femoral vein signal intensity measurements; relative reg

84 e inferior vena cava, iliac veins, or common femoral vein successfully treated with venous stent plac

85 amples were obtained simultaneously from the femoral vein (systemic sample) and the coronary sinus (l

86 of peak oxygen uptake while leg blood flow (femoral vein thermodilution), mean arterial blood pressu

87 Dogs with unilateral femoral vein thrombi were allocated into three groups: (

88 and purity and provided definitive images of femoral vein thrombi within 20 min and pulmonary thrombi

89 ical and yield purity and provided images of femoral vein thrombin in the canine model by 1 hr postin

90 Femoral vein thrombus-to-blood and thrombus-to-muscle ra

91 eous entry into the abdominal aorta from the femoral vein through the adjoining inferior vena cava.

92 s employed in a percutaneous approach from a femoral vein to pierce the right atrial appendage.

93 underwent ferric chloride application on the femoral vein to trigger thrombosis.

94 utive adults with cancer underwent bilateral femoral vein ultrasonography on admission and weekly unt

95 In the femoral vein, W was gradually amplified in the lipopolys

96 One femoral vein was cannulated with a pulmonary artery flot

97 Stent implant into the common femoral vein was required in 44.0% (88/200).

98 lood samples from the coronary sinus and the femoral vein were collected at those time points and the

99 ein thrombosis involving the iliac or common femoral veins were randomized to PCDT with anticoagulati

100 atheters inserted in the internal jugular or femoral veins when catheters are not used for drawing bl

101 Biopsies were performed via the ipsilateral femoral vein with a renal biopsy set designed for transj

102 the brachial artery and internal jugular and femoral veins with plasma and RBC nitric oxide metabolit

103 m cannulae in the inferior vena cava and the femoral veins, with a tie on the inferior vena cava sepa